Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25522860 | 0.80 | CXCR4 (0.38) | CCR1CCR5CCR8HDAC6KEAP1 | |
| SCHEMBL19862557 | 0.79 | L3MBTL1 (0.38) | ALDH1A1RAB9A | |
| SCHEMBL15240118 | 0.79 | GBA1 (0.42) | CCR5ALDH1A1KDM4ERAB9AMAPT | |
| SCHEMBL19862558 | 0.79 | KCNH2 (0.39) | ADORA2A | |
| SCHEMBL19862565 | 0.78 | HRH3 (0.47) | ALDH1A1KDM4ERAB9AMAPTCXCR4 | |
| SCHEMBL14540066 | 0.78 | CCR1 (0.44) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL25522352 | 0.78 | ALDH1A1 (0.38) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL6687544 | 0.77 | CXCR4 (0.37) | CCR1CCR5CCR8HDAC6NOS3 | |
| SCHEMBL19865668 | 0.77 | ADORA2A (0.39) | KDM4EHSD17B10RAB9AMAPTADORA2A | |
| SCHEMBL14477280 | 0.76 | CCR1 (0.43) | CCR1CCR5CCR8HDAC6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| EP-4173674-A1 | IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | CCR1 3250/4885CCR5 1581/4885CCR8 1430/4885 |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | CCR1 2536/4885CCR5 1608/4885CCR8 2513/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | CCR1 3250/4885CCR5 1581/4885CCR8 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.